CHRM3 antisense RNA 2 (CHRM3-AS2)

CHRM3 antisense RNA 2 (CHRM3-AS2) is a long non-coding RNA found to be upregulated in various cancers, notably glioma and ovarian carcinoma[1][2][4]. It is localized predominantly in the cytoplasm and acts as an oncogenic lncRNA by promoting cell viability, colony formation, migration, and invasion, and suppressing apoptosis when expressed at high levels[2][4]. Mechanistically, CHRM3-AS2 functions as a competitive endogenous RNA (ceRNA), particularly by sponging miR-370-5p, which leads to derepression of targets such as KLF4, contributing to tumor progression[1][4]. CHRM3-AS2's expression correlates with immune cell infiltration and activation of key oncogenic and immune pathways, suggesting a significant role in modulating the tumor microenvironment. Its expression level and functional effects make it a potential prognostic biomarker and a candidate for RNA-targeted therapies in cancer[1][2][4].\n\nNo known direct drug interactions exist currently, but RNA-based therapies targeting CHRM3-AS2 are under investigation in preclinical studies[2][4].

Other names

CHRM3 antisense RNA 2 (non-protein coding)CHRM3-AS2

Antisense RNA silencing (e.g., siRNA, shRNA, antisense oligonucleotide targeting); Modulation of miRNA activity (e.g., CHRM3-AS2 acts as a molecular sponge for miR-370-5p, thereby regulating downstream targets such as KLF4)